An alternative treatment proposed in an in vitro study uses a combination of temozolomide and compounds 1 and 2 of N-O-isopropyl sulfonamido-based hydroxamates (MMP-2 inhibitors) to inhibit cancer cell invasiveness and viability (203). This evidence concerns the gene MMP2 and cancer.